Related Experiment Video

Updated: Feb 9, 2026

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

982

Antiatherogenic properties of calcium antagonists

M G Bond1, C Purvis, M Mercuri

  • 1Department of Neurobiology and Anatomy, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, NC 27103.

Journal of Cardiovascular Pharmacology
|January 1, 1991
PubMed

Insights

Calcium antagonists may directly reduce atherosclerosis progression by affecting arterial wall processes. Noninvasive B-mode ultrasonography can monitor these effects on carotid artery disease during early stages.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Atherosclerosis is a complex disease involving arterial wall changes, cholesterol accumulation, and plaque rupture.
  • Calcium antagonists have shown potential in reducing atherosclerosis in animal models, independent of blood pressure effects.

Purpose of the Study:

  • To investigate the direct effects of calcium antagonists on arterial wall processes in atherosclerosis.
  • To evaluate the efficacy of calcium antagonists in inhibiting new lesion development in human subjects.
  • To explore the use of B-mode ultrasonography for monitoring atherosclerosis and treatment effects.

Main Methods:

  • Review of studies on calcium antagonists in hypercholesterolemic animal models.
  • Analysis of human subject trials assessing antiatherosclerosis properties of calcium antagonists.
  • Application of B-mode ultrasonography for noninvasive detection and monitoring of carotid atherosclerosis.

Main Results:

  • Calcium channel blockers appear to have a direct impact on arterial wall processes, suggesting antiatherosclerosis properties.
  • Human studies indicate that calcium antagonists can inhibit the development of new atherosclerotic lesions.
  • B-mode ultrasonography enables noninvasive monitoring of atherosclerosis progression and treatment efficacy.

Conclusions:

  • Calcium antagonists demonstrate direct antiatherosclerosis effects on the arterial wall.
  • B-mode ultrasonography combined with calcium antagonist treatment allows for evaluation of interventions during asymptomatic atherosclerosis.
  • This approach aids in assessing treatment efficacy on arterial wall changes in carotid artery disease.

More Related Videos

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.5K
Cell-based Calcium Assay for Medium to High Throughput Screening of TRP Channel Functions using FlexStation 307:26

Cell-based Calcium Assay for Medium to High Throughput Screening of TRP Channel Functions using FlexStation 3

Published on: August 17, 2011

21.9K

Related Concept Videos

Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
989
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.5K
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.8K
Physical and Chemical Properties of Matter02:57

Physical and Chemical Properties of Matter

The characteristics that enable us to distinguish one substance from another are called properties.
166.8K
Properties of Transition Metals02:58

Properties of Transition Metals

Transition metals are defined as those elements that have partially filled d orbitals. As shown in Figure 1, the d-block elements in groups 3–12 are transition elements. The f-block elements, also called inner transition metals (the lanthanides and actinides), also meet this criterion because the d orbital is partially occupied before the f orbitals.
30.0K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
5.1K